4Tissue: Funding, Investors & Team (Sep 2026)
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges of cell-based treatments.
4Tissue has raised $1.0M across 1 funding round on record, the most recent a Seed of $1.0M announced in Feb 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
4Tissue Company Profile and Key Stats
Latest funding round on record: Feb 2025.
4Tissue Funding Rounds
4Tissue Founders and Leadership Team
No contact details are on record for this team yet.
4Tissue Funding Compared to Other Biotechnology Startups
4Tissue's latest round of $1.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like 4Tissue in Biotechnology and Zwijnaarde
Companies Similar to 4Tissue
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic…
BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global…
4Tissue Funding FAQs
What does 4Tissue do?
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges of cell-based treatments.
How much funding has 4Tissue raised?
4Tissue has raised $1.0M across 1 round on record. The most recent is a Seed of $1.0M announced in Feb 2025.
When did 4Tissue last raise funding?
4Tissue's most recent funding round on record is a Seed of $1.0M, announced in Feb 2025.
Who founded 4Tissue?
FundedIQ lists Lana Van Damme (Founder) at 4Tissue.
Where is 4Tissue headquartered?
4Tissue is based in Zwijnaarde, Oost-Vlaanderen, Belgium.
How many employees does 4Tissue have?
4Tissue is in the 1-10 employee band.
How does 4Tissue's funding compare to other Biotechnology startups?
4Tissue's latest round of $1.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's 4Tissue Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for 4Tissue is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.